Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease.

@article{benussi2026updated,
  title = {{Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease.}},
  author = {Alberto Benussi and Federica Agosta and Luisa Agnello and Alba Rosa Alfano and Mattia Altini and Antonio Antico and Stefania Basilico and Giuseppe Bellelli and Laura Bonanni and Gabriella Bottini and Marco Bozzali and Ovidio Brignoli and Giuseppe Bruno and Annachiara Cagnin and Sonia Francesca Calloni and Stefano F Cappa and Filippo Caraci and Diego Cecchin and Marcello Ciaccio and Sirio Cocozza and Mirco Cosottini and Diego De Leo and Andrea Falini and Lorenzo Gaetani and Nicoletta Gandolfo and Fabio Gotta and Raffaele Lodi and Giancarlo Logroscino and Elena Marcello and Camillo Marra and Walter Marrocco and Silvia Morbelli and Patrizia Mecocci and Enrico Mossello and Lorenzo Palleschi and Pasquale Palumbo and Leonardo Pantoni and Lucilla Parnetti and Luca Roccatagliata and Sandro Sorbi and Patrizia Spadin and Alessandra Splendiani and Alessandro Tessitore and Andrea Ungar and Giuseppe Zappalà and Alessandro Padovani},
  journal = {The journal of prevention of Alzheimer's disease},
  year = {2026},
  month = oct,
  doi = {10.1016/j.tjpad.2026.100685},
  url = {https://europepmc.org/article/MED/42880054},
  note = {CC BY-NC-ND},
}

TY  - JOUR
TI  - Updated Italian intersocietal recommendations for the appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease.
AU  - Alberto Benussi
AU  - Federica Agosta
AU  - Luisa Agnello
AU  - Alba Rosa Alfano
AU  - Mattia Altini
AU  - Antonio Antico
AU  - Stefania Basilico
AU  - Giuseppe Bellelli
AU  - Laura Bonanni
AU  - Gabriella Bottini
AU  - Marco Bozzali
AU  - Ovidio Brignoli
AU  - Giuseppe Bruno
AU  - Annachiara Cagnin
AU  - Sonia Francesca Calloni
AU  - Stefano F Cappa
AU  - Filippo Caraci
AU  - Diego Cecchin
AU  - Marcello Ciaccio
AU  - Sirio Cocozza
AU  - Mirco Cosottini
AU  - Diego De Leo
AU  - Andrea Falini
AU  - Lorenzo Gaetani
AU  - Nicoletta Gandolfo
AU  - Fabio Gotta
AU  - Raffaele Lodi
AU  - Giancarlo Logroscino
AU  - Elena Marcello
AU  - Camillo Marra
AU  - Walter Marrocco
AU  - Silvia Morbelli
AU  - Patrizia Mecocci
AU  - Enrico Mossello
AU  - Lorenzo Palleschi
AU  - Pasquale Palumbo
AU  - Leonardo Pantoni
AU  - Lucilla Parnetti
AU  - Luca Roccatagliata
AU  - Sandro Sorbi
AU  - Patrizia Spadin
AU  - Alessandra Splendiani
AU  - Alessandro Tessitore
AU  - Andrea Ungar
AU  - Giuseppe Zappalà
AU  - Alessandro Padovani
PY  - 2026
DA  - 2026/10/15
JO  - The journal of prevention of Alzheimer's disease
DO  - 10.1016/j.tjpad.2026.100685
UR  - https://europepmc.org/article/MED/42880054
AB  - With the European authorisation of lecanemab and donanemab, Italy is entering the era of disease-modifying therapy for early symptomatic Alzheimer's disease. The Italian Expert Panel on Alzheimer (EPA), which convened 21 scientific societies and patient associations and published a first set of intersocietal recommendations in 2025, was reconvened in Rome on 24 January 2026 (EPA2) to address the operational gaps that had emerged during the implementation of that document. A modified Delphi process was adopted to formalise consensus on the most controversial points raised during the meeting. Thirty-six declarative statements covering five domains, namely the tiered organisation of the Centres for Cognitive Disorders and Dementia (CDCD), clinical staging and treatment monitoring, eligibility considerations in mild cognitive impairment and atypical phenotypes, composition of the multidisciplinary team, and magnetic resonance imaging thresholds, ARIA monitoring and biomarker pathway, were submitted to a multidisciplinary panel of experts. Strong agreement was reached on the large majority of statements, providing quantitative endorsement for a competence-based reorganisation of the CDCD network, the harmonised use of the Clinical Dementia Rating, an explicit composition of the multidisciplinary team, trial-aligned magnetic resonance imaging eligibility criteria with a move towards risk-adapted ARIA monitoring, and a stepwise biomarker pathway integrating plasma assays, cerebrospinal fluid analysis on automated platforms and amyloid positron emission tomography. The document provides Italian regional and national health systems, prescribing centres and reimbursing authorities with a quantitative blueprint for the appropriate, equitable and sustainable use of anti-amyloid monoclonal antibodies in clinical practice.
SN  - 2426-0266
ER  -